CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
LY3039478drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02917733
NCT02917733Phase 1Completed
CompareCT.gov

Disposition of [¹⁴C₂]-Labeled LY3039478 Following Oral Administration in Healthy Subjects

Eli Lilly and Company·interventional·Posted Sep 28, 2016·Updated Jul 28, 2025

In Brief

A Phase 1 clinical trial evaluating LY3039478 for Healthy. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This type of study is called a radiolabeled study. For this study, LY3039478 (study drug) has been specially prepared to contain radiolabeled carbon \[¹⁴C\]. \[¹⁴C\] is a naturally occurring radioactive form of the element carbon. This study will help determine how the drug appears in the blood, urine, and stool after it is administered by mouth to healthy people. Information about any side effects that may occur will also be collected. This study will last about 10 weeks for each participant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 28, 2016
Enrollment StartSep 1, 2016
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.8 years ago

Interventions

LY3039478drug

Administered orally